Small-Cap Firm Century Therapeutics' Expands into Autoimmune Diseases, Analyst Says Clade Therapeutics Acquisition Intriguing

8d ago, source:

Century Therapeutics unveils plans to expand CNTY-101 clinical development into additional autoimmune diseases, including ...

Buy Rating Affirmed for Century Therapeutics Amidst Strong Financial Backing and Promising Clinical Advances

3d ago, source:

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on IPSC stock, giving a Buy rating on April 12. Daina Graybosch ...

IPSC Century Therapeutics, Inc.

14d ago, source: Seeking Alpha

Century Therapeutics, Inc., a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies.

Century Therapeutics gets grant for universal chimeric antigen receptor system with adaptable receptor specificity

4d ago, source: Pharmaceutical Technology

Revolutionize disease treatment with Century Therapeutics' patented universal chimeric antigen receptor system. Discover how this adaptable system uses immune effector cells and soluble polypeptides ...

How Much Upside is Left in Century Therapeutics, Inc. (IPSC)? Wall Street Analysts Think 193.4%

1mon ago, source: Hosted on MSN

S hares of Century Therapeutics, Inc. (IPSC) have gained 9.7% over the past four weeks to close the last trading session at $5, but there could still be a solid upside left in the stock if short ...

Century Therapeutics Inc.

23d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Century Therapeutics Inc IPSC

26d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...